comparemela.com

Page 5 - David Stamler News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024

– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference –

United statesSan franciscoRemy bernardaHannah howlettDanielo claassenDavid stamlerMargaret bradburyDaniel claassenAlterity therapeuticsNonclinical developmentAmerican academy of neurologyVanderbilt universityNational institute of healthInternational conferenceParkinson foundationVanderbilt university medical center

Alterity Therapeutics Phase 2 Data Monitoring Committee

- ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, AUSTRALIA AND SAN FRANCISCO, Feb. 06,.

San franciscoUnited statesDavid stamlerRemy bernardaHannah howlettEuropean commissionAlterity therapeuticsDrug administrationData monitoring committeeLine data expectedChief executive officerMultiple system atrophySystem atrophyMedia contactsSecurities actAustralian stock exchange ath ax

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

- ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, AUSTRALIA AND SAN FRANCISCO, Feb. 06, 2024 Alterity Therapeutics , a.

United statesSan franciscoHannah howlettRemy bernardaDavid stamlerDrug administrationData monitoring committeeSecurities exchangeSystem atrophy national institute of neurological disordersAlterity therapeuticsEuropean commissionLine data expectedChief executive officerMultiple system atrophySystem atrophyNational institute

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

MELBOURNE, Australia and SAN FRANCISCO, Jan. 29, 2024 Alterity Therapeutics , a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today.

San franciscoUnited statesRemy bernardaHannah howlettDavid stamlerAlterity therapeuticsChief executive officerSharecafe hidden gemsMedia contacts

Alterity Therapeutics Issues Shareholder Letter

– Preliminary Data from ATH434-202 Study Expected in 1H 2024 –– ATH434-201 Study to Complete in November 2024 – MELBOURNE, Australia and SAN.

San franciscoUnited statesDavid stamlerAlterity therapeuticsVanderbilt university medical centerEuropean commissionPreliminary dataMultiple system atrophyOrphan drug designationChief executive officerMultiple systemSecurities actAustralian stock exchange ath axAlterity therapeutics limitedAlterity therapeuticsMultiple system atrophy

vimarsana © 2020. All Rights Reserved.